Next-Generation Hydrocortisone Sodium Phosphate Formulations and Delivery Systems

This inventive concept envisions a next-generation platform for hydrocortisone sodium phosphate formulations and delivery systems, offering improved efficacy, convenience, and patient compliance. It encompasses novel transdermal, topical, oral, and inhalation formulations, as well as innovative manufacturing processes, to address the limitations of current treatments.

The original patent disclosed an aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol. However, these formulations have limitations in terms of bioavailability, skin penetration, and patient convenience. The new inventive concept addresses these limitations by introducing novel formulations, delivery systems, and manufacturing processes that provide enhanced therapeutic outcomes and improved patient experience.

The new inventive concept comprises four main aspects: (1) a transdermal delivery system featuring a wearable patch with a hydrogel matrix containing monothioglycerol, (2) a topical formulation encapsulated in nanoparticles for enhanced skin penetration, (3) an oral formulation utilizing a hydrocortisone sodium phosphate prodrug and a monothioglycerol derivative to improve bioavailability, and (4) an inhalation device employing a liposomal carrier to deliver hydrocortisone sodium phosphate and monothioglycerol. Additionally, a novel manufacturing process involving lyophilization and reconstitution with a buffer solution enables the production of stable liquid formulations.

The new claims introduce novel formulations, delivery systems, and manufacturing processes that are not obvious from the original patent. The use of wearable patches, nanoparticles, prodrugs, and liposomal carriers, as well as the innovative manufacturing process, provide a significant departure from the prior art and demonstrate a non-obvious inventive step.

Alternative embodiments of the inventive concept could include variations in the hydrogel matrix composition, nanoparticle design, prodrug structure, and liposomal carrier formulation. Additionally, the manufacturing process could be adapted to accommodate different buffer solutions or lyophilization conditions.

The next-generation hydrocortisone sodium phosphate formulations and delivery systems have significant commercial potential in the pharmaceutical industry, particularly in the treatment of inflammatory skin conditions, allergic reactions, and other indications where hydrocortisone is currently used. The target market includes pharmaceutical companies, dermatology and allergy clinics, and patients seeking more effective and convenient treatments.